Metotrexato en artritis idiopática juvenil: efectos adversos y factores asociados

Barral Mena, Estefanía; García Cárdaba, Luis Miguel; Canet Tarrés, Anna; Enríquez Merayo, Eugenia; Cruz Utrilla, Alejandro; Inocencio Arocena, Jaime de.
An. pediatr. (2003. Ed. impr.) ; 92(3): 124-131, mar. 2020. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-196280

Documentos relacionados

  1. The influence of methotrexate on hair loss while using immunomodulatory doses.
  2. 2023 International Consensus Guidance for the use of Tripterygium Wilfordii Hook F in the treatment of active rheumatoid arthritis.
  3. Oral Versus Subcutaneous Methotrexate in Immune-Mediated Inflammatory Disorders: an Update of the Current Literature.
  4. Development of Methotrexate Complexes Endowed with New Biological Properties Envisioned for Musculoskeletal Regeneration in Rheumatoid Arthritis Environments.
  5. Rhein methotrexate-decorated solid lipid nanoparticles altering adjuvant arthritis progression through endoplasmic reticulum stress-mediated apoptosis.
  6. Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort.
  7. Treating rheumatoid arthritis.
  8. Undifferentiated arthritis: a changing population who did not benefit from enhanced disease-modifying anti-rheumatic drug strategies-results from a 25 year longitudinal inception cohort.
  9. Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3).
  10. Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.